Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions

Inclusion Criteria: * Age ≥ 18 years, eligible for a diagnostic and/or therapeutic endoscopy; * At least a suspicion of low grade dysplasia (LGD) based on a prior endoscopy; * World Health Organization (WHO) performance score of 0-2; * Written informed consent; * Mentally competent person that is able and willing to comply with study procedures; * For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs or are less than 2 years post-menopausal: * A negative serum pregnancy test prior to receiving the tracer; * Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter. Exclusion Criteria: * Pregnancy or breast feeding; * Advanced stage EAC patient not suitable for endoscopic resection; * Medical or psychiatric conditions that compromise the patient's ability to give informed consent; * Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last three months prior to the start of the treatment * The subject has been included previously in this study or has been injected with another investigational medicinal product within the past six months. * History of myocardial infarction (MI), Transient Ischemic Attack (TIA), CerebroVascular Accident (CVA), pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment. * The subject had any significant change in their regular prescription or non-prescription medication between 14 days and 1 day prior to Investigational Medicinal Product (IMP) administration. Occasional use of analgesics, such as non-steroid anti-inflammatory drugs and/or paracetamol, was permitted at the discretion of the investigator. Use of hormonal contraceptives is permitted.